Literature DB >> 3033289

Transcriptional trans-activation by the human papillomavirus type 16 E2 gene product.

W C Phelps, P M Howley.   

Abstract

We identified a conditional transcriptional enhancer in the long control region (LCR) of human papillomavirus type 16 (HPV-16). This conditional enhancer requires activation in trans by a product of the viral early-region open reading frames (ORFs). Primer extension analysis of chloramphenicol acetyltransferase RNA isolated from transiently transfected CV-1 cells demonstrated that trans-activation of the HPV-16 LCR enhancer operated at the transcriptional level. Mutational analysis of the early ORFs demonstrated that the conditional enhancer of the LCR was trans-activated by the product of the E2 ORF. The E2 gene product of bovine papillomavirus type 1, which can trans-activate the conditional enhancer in the bovine papillomavirus type 1 LCR, was also capable of trans-activating the E2-responsive enhancer of HPV-16. The activity of the HPV-16 LCR enhancer was also assayed in two human cervical carcinoma cell lines, HeLa and SiHa, which harbor transcriptionally active, integrated HPV-18 and HPV-16 DNA sequences, respectively. No endogenous E2 or E2-like activity was detected in either cell line.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3033289      PMCID: PMC254145          DOI: 10.1128/JVI.61.5.1630-1638.1987

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Transient gene expression control: effects of transfected DNA stability and trans-activation by viral early proteins.

Authors:  J C Alwine
Journal:  Mol Cell Biol       Date:  1985-05       Impact factor: 4.272

2.  Human papillomavirus types 16 and 18 sequences in carcinoma cell lines of the cervix.

Authors:  M M Pater; A Pater
Journal:  Virology       Date:  1985-09       Impact factor: 3.616

3.  Transactivation of a bovine papilloma virus transcriptional regulatory element by the E2 gene product.

Authors:  B A Spalholz; Y C Yang; P M Howley
Journal:  Cell       Date:  1985-08       Impact factor: 41.582

4.  Simian virus 40 enhancer increases RNA polymerase density within the linked gene.

Authors:  F Weber; W Schaffner
Journal:  Nature       Date:  1985 May 2-8       Impact factor: 49.962

5.  Cloning of monomeric human papillomavirus type 16 DNA integrated within cell DNA from a cervical carcinoma.

Authors:  T Matsukura; T Kanda; A Furuno; H Yoshikawa; T Kawana; K Yoshiike
Journal:  J Virol       Date:  1986-06       Impact factor: 5.103

6.  The nucleotide sequence and genome organization of human papilloma virus type 11.

Authors:  K Dartmann; E Schwarz; L Gissmann; H zur Hausen
Journal:  Virology       Date:  1986-05       Impact factor: 3.616

7.  Cloning and characterization of the DNA of a new human papillomavirus from a woman with dysplasia of the uterine cervix.

Authors:  A T Lorincz; W D Lancaster; G F Temple
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

8.  Dissociation of transforming and trans-activation functions for bovine papillomavirus type 1.

Authors:  Y C Yang; B A Spalholz; M S Rabson; P M Howley
Journal:  Nature       Date:  1985 Dec 12-18       Impact factor: 49.962

9.  Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines.

Authors:  C Yee; I Krishnan-Hewlett; C C Baker; R Schlegel; P M Howley
Journal:  Am J Pathol       Date:  1985-06       Impact factor: 4.307

10.  trans Activation of the simian virus 40 late transcription unit by T-antigen.

Authors:  J Brady; G Khoury
Journal:  Mol Cell Biol       Date:  1985-06       Impact factor: 4.272

View more
  74 in total

1.  Ski interacts with the evolutionarily conserved SNW domain of Skip.

Authors:  T Prathapam; C Kühne; M Hayman; L Banks
Journal:  Nucleic Acids Res       Date:  2001-09-01       Impact factor: 16.971

2.  Cornifin, a cross-linked envelope precursor in keratinocytes that is down-regulated by retinoids.

Authors:  K W Marvin; M D George; W Fujimoto; N A Saunders; S H Bernacki; A M Jetten
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

3.  Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein.

Authors:  W C Phelps; K Münger; C L Yee; J A Barnes; P M Howley
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

Review 4.  Mechanisms of human papillomavirus-induced oncogenesis.

Authors:  Karl Münger; Amy Baldwin; Kirsten M Edwards; Hiroyuki Hayakawa; Christine L Nguyen; Michael Owens; Miranda Grace; Kyungwon Huh
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

5.  Identification of the human papillomavirus E2 protein in genital tract tissues.

Authors:  C C Li; R V Gilden; S D Showalter; K V Shah
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

6.  Brd4 is required for e2-mediated transcriptional activation but not genome partitioning of all papillomaviruses.

Authors:  M G McPhillips; J G Oliveira; J E Spindler; R Mitra; A A McBride
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

7.  Levels of the E2 interacting protein TopBP1 modulate papillomavirus maintenance stage replication.

Authors:  Sriramana Kanginakudru; Marsha DeSmet; Yanique Thomas; Iain M Morgan; Elliot J Androphy
Journal:  Virology       Date:  2015-02-07       Impact factor: 3.616

8.  Analysis of trans activation by human papillomavirus type 16 E7 and adenovirus 12S E1A suggests a common mechanism.

Authors:  W C Phelps; S Bagchi; J A Barnes; P Raychaudhuri; V Kraus; K Münger; P M Howley; J R Nevins
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

9.  Transactivation by the E2 protein of oncogenic human papillomavirus type 31 is not essential for early and late viral functions.

Authors:  F Stubenrauch; A M Colbert; L A Laimins
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

10.  Activation of immunoglobulin control elements in transgenic mice.

Authors:  A E Miller; D L Ennist; K Ozato; H Westphal
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.